4TEEN4 PHARMACEUTICALS
4TEEN4 Pharmaceuticals GmbH is a biopharmaceutical company developing Procizumab, a humanized antibody targeting human Dipeptidyl Peptidase 3 (DPP3) for the treatment of acute cardiovascular diseases.
4TEEN4 PHARMACEUTICALS
Industry:
Biotechnology Health Care Health Diagnostics Hospital Medical Medical Device
Founded:
2002-01-01
Address:
Hennigsdorf, Brandenburg, Germany
Country:
Germany
Website Url:
http://www.4teen4.de
Total Employee:
11+
Status:
Active
Contact:
+49 33 02/2 05 65-0
Email Addresses:
[email protected]
Total Funding:
38.86 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Google Universal Analytics Apache
Similar Organizations
Flamentera
Flamentera AG develops non-invasive tests for lifelong monitoring of celiac patients.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Injectsense
Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.
Natural Diagnostics
Natural Diagnostics has develops environmentally friendly pregnancy tests and ovulation tests with 85% less plastic than conventional tests.
Reavita
Reavita is specialized in diagnostics, resuscitation and simulation for medical laypersons and medical professionals.
SomaLogic
SomaLogic is a protein biomarker discovery and clinical diagnostics company, offers SOMAmer technology to improve diagnostic products.
Sphingotec GmbH
SphingoTec develops innovative biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions.
xRapid
xRapid is a mobile health diagnosis through disruptive solutions leveraging the use of artificial intelligence.
Current Advisors List
Current Employees Featured
Founder
Investors List
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Convertible Note - 4TEEN4 Pharmaceuticals
Brandenburg Kapital
Brandenburg Kapital investment in Series A - 4TEEN4 Pharmaceuticals
HBM Partners
HBM Partners investment in Venture Round - 4TEEN4 Pharmaceuticals
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Venture Round - 4TEEN4 Pharmaceuticals
Wellington Partners
Wellington Partners investment in Venture Round - 4TEEN4 Pharmaceuticals
Brandenburg Kapital
Brandenburg Kapital investment in Venture Round - 4TEEN4 Pharmaceuticals
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - 4TEEN4 Pharmaceuticals
Official Site Inspections
http://www.4teen4.de
- Host name: www633.your-server.de
- IP address: 168.119.26.113
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "4TEEN4 Pharmaceuticals"
Start - 4TEEN4 Pharmaceuticals GmbH
Cardiogenic shock mortality rate exceeds 70% in intensive care units. Cardiogenic shock is an acute and life-threatening medical emergency, usually caused by an acute myocardial injury, like a heart attack, resulting in left …See details»
About Us - 4TEEN4 Pharmaceuticals GmbH
4TEEN4 Pharmaceuticals GmbH is developing Procizumab, an inhibitor of DPP3 pathway. A breakthrough, first-in-class Phase I asset with clinical proof of concept to restore cardiac function and prevent death due to Cardiogenic Shock an …See details»
4TEEN4 Pharmaceuticals - Crunchbase Company Profile & Funding
4TEEN4 Pharmaceuticals GmbH is a biopharmaceutical company developing Procizumab, a humanized antibody targeting human Dipeptidyl Peptidase 3 (DPP3) for the treatment of acute …See details»
4TEEN4 Pharmaceuticals GmbH - Drug pipelines, Patents ... - Patsnap
Explore 4TEEN4 Pharmaceuticals GmbH with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 1 news, and 2 literature, Disease Domain:Infectious Diseases, …See details»
4TEEN4 Pharmaceuticals (fka Sphingotec Therapeutics)
4TEEN4 Pharmaceuticals GmbH is a company with a clear mission: improving the management of critically ill patients. Our focus lies on patients suffering from diseases related to massive …See details»
4TEEN4 Pharmaceuticals Selects AGC Biologics to …
SEATTLE – December 01, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals …See details»
4TEEN4 Pharmaceuticals GmbH at the Swiss Biotech Day
4TEEN4 Pharmaceuticals is developing Procizumab, an inhibitor of DPP3 pathway. A breakthrough, first in class asset with pre-clinical proof of concept to restore cardiac function …See details»
Media - 4TEEN4 Pharmaceuticals GmbH
Stay updated with the latest news and publications from 4TEEN4 Pharmaceuticals GmbH. Our News and Publications page offers insights into our groundbreaking research, developments …See details»
4TEEN4 Pharmaceuticals Selects AGC Biologics to ... - Yahoo Finance
Dec 1, 2021 AGC Biologics to produce Procizumab for early and late clinical phases at company’s Chiba and Copenhagen facilitiesSeattle, Dec. 01, 2021 (GLOBE NEWSWIRE) -- …See details»
What is 4TEEN4 Pharmaceuticals? Company Culture, Mission, Values
See what employees say it's like to work at 4TEEN4 Pharmaceuticals. Salaries, reviews, and more - all posted by employees working at 4TEEN4 Pharmaceuticals.See details»
Biotech-Startup 4TEEN4 Pharmaceuticals schließt 7-Millionen-Euro ...
Dec 5, 2019 Die 4TEEN4 Pharmaceuticals GmbH (ehemals Sphingotec Therapeutics GmbH) gibt den Abschluss einer Finanzierungsrunde der Serie A in Höhe von 6,9 Millionen Euro …See details»
Neue Therapie bei Herzinfarkt und Blutvergiftung
Oct 31, 2024 Die Biotechfirma 4Teen4 hat ein Mittel entwickelt, das Patienten vor dem Tod durch Organversagen nach Herzinfarkt oder Blutvergiftung bewahren soll. Es könnte einen …See details»
4TEEN4 Pharmaceuticals - Craft
4TEEN4 Pharmaceuticals has 5 employees at their 1 location and $38.77 m in total funding,. See insights on 4TEEN4 Pharmaceuticals including office locations, competitors, revenue, …See details»
4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture
Dec 1, 2021 AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest …See details»
Career - 4TEEN4 Pharmaceuticals GmbH
4TEEN4 Pharmaceuticals is built on science, innovation, and dedication, where you can use your enthusiasm in changing patients’ lives and creating impact. We are a fast-growing, small …See details»
4TEEN4 Pharmaceuticals-动脉网 - vbdata.cn
4TEEN4 Pharmaceuticals GmbH是一家使命明确的公司：改善重症患者的管理，这些患者患有与大量细胞死亡相关的疾病，从而导致不受控制的二肽基肽酶3（DPP3）释放到血液中。基于证 …See details»
Neuer Wirkstoff gegen Organversagen: Sieben Millionen Euro für ...
Dec 10, 2019 Das Biotech-Startup 4TEEN4 Pharmaceuticals aus Henningsdorf bei Berlin, hat sich eine Finanzierung von 6,9 Millionen Euro gesichert. Mit dem Geld soll ein Wirkstoff für …See details»
4TEEN4 Pharmaceuticals GmbH (4TEEN4 Pharmaceuticals GmbH)
了解4TEEN4 Pharmaceuticals GmbH (4TEEN4 Pharmaceuticals GmbH)公司的药物管线，治疗领域，技术平台，以及它的2项临床试验, 1篇新闻和2篇文献，疾病领域:感染，技术平台:单克隆 …See details»
Biotech-Startup 4TEEN4 Pharmaceuticals schließt 7-Millionen-Euro ...
Hennigsdorf/Berlin, 05.12.2019. Die 4TEEN4 Pharmaceuticals GmbH (ehemals Sphingotec Therapeutics GmbH) gibt den Abschluss einer Finanzierungsrunde der Serie A in Höhe von …See details»
4TEEN4
Die 4TEEN4 Pharmaceuticals GmbH entwickelt einen neuartigen Ansatz zur Diagnostik und Behandlung eines unlängst entdeckten Krankheitsmechanismus, der in direktem …See details»